Breaking News

Penn Pharma Adds to Senior Management Team

December 11, 2012

Jones to head commercial operations

Kat Jones has been appointed director, marketing and commercial operations at Penn Pharma. Ms. Jones will be based out of the company’s Tredegar offices in South Wales, where the company is launching its new contained manufacturing operation. She will also serve on the company’s executive board.
 
Ms. Jones has more than 18 years of experience in various senior sales and marketing roles. Previously, she worked on a consultancy basis and has held positions at Bupa, Archimedes, Pfizer Marketing, and Aventis.
 
Chief executive officer Dr. Richard Yarwood said, “2013 is going to be a significant year for us at Penn Pharma and so it is vital we have the right components in place to support the demand for both our existing and new services.  Kat has the perfect attitude, experience and approach to making sure our client base continues to receive the expertise and service they require, whilst making sure the world knows about our new contained facility and I am confident that Kat is just the person to help us make that known to the industry and really put Penn Pharma on the map.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important